文献速递认知障碍与痴呆

血浆淀粉样蛋白β42/40检测阿尔茨海默病淀粉样斑块的验证

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
PubMed 文献 · Neurology · 2021-12-14

研究采用高精度免疫沉淀质谱法(IPMS)检测三个国家AD研究队列共465份血浆样本的Aβ42/Aβ40,与淀粉样PET和脑脊液Aβ42/Aβ40参考标准比较。血浆Aβ42/Aβ40与淀粉样PET状态一致性良好(AUC 0.84,95%CI 0.80-0.87),加入APOE ε4携带状态后提高至0.88(95%CI 0.85-0.91)。与脑脊液淀粉样状态AUC为0.85(95%CI 0.78-0.91),加入APOE ε4后提高至0.93(95%CI 0.89-0.97)。

要点

  • 血浆Aβ42/Aβ40与淀粉样PET状态一致性良好,AUC 0.84(95%CI 0.80-0.87)。
  • 加入APOE ε4携带状态后AUC提高至0.88(95%CI 0.85-0.91)。
  • 与脑脊液淀粉样状态AUC 0.85(95%CI 0.78-0.91),加入APOE ε4后0.93(95%CI 0.89-0.97)。

核心结论

  • 血浆Aβ42/Aβ40是检测淀粉样斑块的稳健指标,可用于辅助AD诊断、识别未来AD痴呆风险者,并提高AD研究和临床试验入组人群的多样性。
  • 本研究提供II级证据:高精度IPMS法检测的血浆Aβ42/Aβ40在认知正常和认知受损研究参与者中均能准确诊断脑淀粉样变性。

研究设计与样本

  • 诊断准确性研究,血浆样本465份来自美国(n=182)、澳大利亚(n=183)和瑞典(n=100)三个大型AD研究队列。
  • 采用高精度免疫沉淀质谱法(IPMS)检测血浆Aβ42/Aβ40,参考标准为淀粉样PET和脑脊液Aβ42/Aβ40。

主要发现

  • 合并465名参与者中,血浆Aβ42/Aβ40与淀粉样PET状态一致性良好,AUC 0.84(95%CI 0.80-0.87)。
  • 加入APOE ε4携带状态后一致性提高,AUC 0.88(95%CI 0.85-0.91)。
  • 血浆Aβ42/Aβ40与脑脊液淀粉样状态AUC为0.85(95%CI 0.78-0.91),加入APOE ε4状态后提高至0.93(95%CI 0.89-0.97)。
  • 三个队列结果一致,尽管方案存在差异;在认知正常和认知受损个体中检测表现相似。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To determine the diagnostic accuracy of a plasma Aβ42/Aβ40 assay in classifying amyloid PET status across global research studies using samples collected by multiple centers that utilize different blood collection and processing protocols. METHODS: Plasma samples (n = 465) were obtained from 3 large Alzheimer disease (AD) research cohorts in the United States (n = 182), Australia (n = 183), and Sweden (n = 100). Plasma Aβ42/Aβ40 was measured by a high precision immunoprecipitation mass spectrometry (IPMS) assay and compared to the reference standards of amyloid PET and CSF Aβ42/Aβ40. RESULTS: In the combined cohort of 465 participants, plasma Aβ42/Aβ40 had good concordance with amyloid PET status (receiver operating characteristic area under the curve [AUC] 0.84, 95% confidence interval [CI] 0.80-0.87); concordance improved with the inclusion of APOE ε4 carrier status (AUC 0.88, 95% CI 0.85-0.91). The AUC of plasma Aβ42/Aβ40 with CSF amyloid status was 0.85 (95% CI 0.78-0.91) and improved to 0.93 (95% CI 0.89-0.97) with APOE ε4 status. These findings were consistent across the 3 cohorts, despite differences in protocols. The assay performed similarly in both cognitively unimpaired and impaired individuals. DISCUSSION: Plasma Aβ42/Aβ40 is a robust measure for detecting amyloid plaques and can be utilized to aid in the diagnosis of AD, identify those at risk for future dementia due to AD, and improve the diversity of populations enrolled in AD research and clinical trials. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that plasma Aβ42/Aβ40, as measured by a high precision IPMS assay, accurately diagnoses brain amyloidosis in both cognitively unimpaired and impaired research participants.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Li Y, Schindler SE, Bollinger JG, et al. Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology. 2021. PMID: 34906975. doi:10.1212/WNL.0000000000013211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。